DE3223087C2 - Verfahren zur Reinigung von Interferon - Google Patents
Verfahren zur Reinigung von InterferonInfo
- Publication number
- DE3223087C2 DE3223087C2 DE3223087A DE3223087A DE3223087C2 DE 3223087 C2 DE3223087 C2 DE 3223087C2 DE 3223087 A DE3223087 A DE 3223087A DE 3223087 A DE3223087 A DE 3223087A DE 3223087 C2 DE3223087 C2 DE 3223087C2
- Authority
- DE
- Germany
- Prior art keywords
- interferon
- ifn
- beta
- adsorbent
- macromolecular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108010050904 Interferons Proteins 0.000 title claims abstract description 51
- 102000014150 Interferons Human genes 0.000 title claims abstract description 50
- 229940079322 interferon Drugs 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims abstract description 46
- 229920002239 polyacrylonitrile Polymers 0.000 claims abstract description 8
- 238000000746 purification Methods 0.000 claims abstract description 6
- 239000003463 adsorbent Substances 0.000 claims description 13
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 5
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims description 4
- 239000002657 fibrous material Substances 0.000 claims description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
- OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 2
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 claims description 2
- 238000011084 recovery Methods 0.000 abstract description 4
- 230000000840 anti-viral effect Effects 0.000 abstract description 2
- 239000000872 buffer Substances 0.000 abstract description 2
- 230000003217 anti-cancerogenic effect Effects 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 102000003996 Interferon-beta Human genes 0.000 description 13
- 108090000467 Interferon-beta Proteins 0.000 description 13
- 239000000835 fiber Substances 0.000 description 13
- 229960001388 interferon-beta Drugs 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 9
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 8
- 102000006992 Interferon-alpha Human genes 0.000 description 8
- 108010047761 Interferon-alpha Proteins 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 7
- 235000002639 sodium chloride Nutrition 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920000297 Rayon Polymers 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000002964 rayon Substances 0.000 description 3
- -1 Acryl Chemical group 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 229920002466 Dynel Polymers 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920001617 Vinyon Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000001064 anti-interferon Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56118865A JPS5821691A (ja) | 1981-07-29 | 1981-07-29 | α−及びβ−インタ−フェロンの精製方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3223087A1 DE3223087A1 (de) | 1983-02-17 |
| DE3223087C2 true DE3223087C2 (de) | 1985-11-14 |
Family
ID=14747035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3223087A Expired DE3223087C2 (de) | 1981-07-29 | 1982-06-21 | Verfahren zur Reinigung von Interferon |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4465622A (OSRAM) |
| JP (1) | JPS5821691A (OSRAM) |
| CA (1) | CA1185178A (OSRAM) |
| DE (1) | DE3223087C2 (OSRAM) |
| FR (1) | FR2510409A1 (OSRAM) |
| GB (1) | GB2111061B (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5702699A (en) * | 1982-09-23 | 1997-12-30 | Cetus Corporation | Process for the recovery of lipophilic proteins |
| US5385738A (en) * | 1983-10-14 | 1995-01-31 | Sumitomo Pharmaceuticals Company, Ltd. | Sustained-release injection |
| US4855134A (en) * | 1983-10-14 | 1989-08-08 | Sumitomo Pharmaceuticals Company, Limited | Sustained-release preparation |
| EP0150067A3 (en) * | 1984-01-23 | 1986-12-30 | Takeda Chemical Industries, Ltd. | Stable composition of gamma-interferon |
| JPS60228422A (ja) * | 1984-04-26 | 1985-11-13 | Suntory Ltd | 安定化された生理活性物質製剤 |
| JPS60243028A (ja) * | 1984-04-28 | 1985-12-03 | Kyowa Hakko Kogyo Co Ltd | インタ−フエロンの可溶化方法 |
| EP0168008A3 (en) * | 1984-07-10 | 1986-12-30 | Takeda Chemical Industries, Ltd. | Stable composition of gamma-interferon |
| WO1986000531A1 (fr) * | 1984-07-10 | 1986-01-30 | Takeda Chemical Industries, Ltd. | Composition a base de gamma-interferon |
| US4873312A (en) * | 1985-04-25 | 1989-10-10 | Amgen | Method for purifying interferon and composition of matter produced thereby |
| DE3628468A1 (de) * | 1986-08-21 | 1988-03-03 | Thomae Gmbh Dr K | Neue applikationsformen fuer (alpha)-interferone |
| CA2024046A1 (en) * | 1989-09-28 | 1991-03-29 | Alberto Ferro | Stabilized leukocyte-interferons |
| ATE117088T1 (de) * | 1990-01-27 | 1995-01-15 | Roland Man Druckmasch | Verfahren und vorrichtung zur messung des alkoholgehalts der feuchtflüssigkeit eines feuchtwerks einer offset-druckmaschine. |
| IT1272252B (it) | 1994-05-16 | 1997-06-16 | Applied Research Systems | Formulazioni liquide di interferone beta |
| US5861174A (en) * | 1996-07-12 | 1999-01-19 | University Technology Corporation | Temperature sensitive gel for sustained delivery of protein drugs |
| US20030190307A1 (en) * | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
| US6433144B1 (en) * | 1999-01-12 | 2002-08-13 | Viragen, Inc. | Compositions of highly-purified natural mixtures of type I Interferon derived from leukocytes and methods |
| EP1343518B1 (en) * | 2000-11-07 | 2009-07-22 | Novartis Vaccines and Diagnostics, Inc. | Stabilized interferon compositions |
| US6887462B2 (en) * | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
| UY27373A1 (es) * | 2001-07-09 | 2003-02-28 | Schering Ag | Formulaciones de interferón beta-humano |
| US7367961B2 (en) * | 2004-09-10 | 2008-05-06 | Depuy Spine, Inc. | Intradiscal injection of autologous interferon |
| CN113845560A (zh) * | 2020-06-28 | 2021-12-28 | 佛山汉腾生物科技有限公司 | 目的蛋白纯化方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4810232B1 (OSRAM) * | 1970-09-04 | 1973-04-02 | ||
| FR2351665A1 (fr) * | 1976-05-21 | 1977-12-16 | Elf Aquitaine | Procede de purification de preparations possedant notamment une activite interferon, preparations purifiees ainsi obtenues et leur application en tant que medicament |
| NL7605805A (nl) * | 1976-05-28 | 1977-11-30 | Stichting Rega V Z W | Werkwijze voor het zuiveren van interferon. |
-
1981
- 1981-07-29 JP JP56118865A patent/JPS5821691A/ja active Granted
-
1982
- 1982-06-07 US US06/385,872 patent/US4465622A/en not_active Expired - Fee Related
- 1982-06-16 GB GB08217388A patent/GB2111061B/en not_active Expired
- 1982-06-21 DE DE3223087A patent/DE3223087C2/de not_active Expired
- 1982-07-06 CA CA000406723A patent/CA1185178A/en not_active Expired
- 1982-07-29 FR FR8213278A patent/FR2510409A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| CA1185178A (en) | 1985-04-09 |
| JPS5821691A (ja) | 1983-02-08 |
| DE3223087A1 (de) | 1983-02-17 |
| FR2510409B1 (OSRAM) | 1984-06-22 |
| FR2510409A1 (fr) | 1983-02-04 |
| GB2111061B (en) | 1984-11-21 |
| JPS6254440B2 (OSRAM) | 1987-11-14 |
| GB2111061A (en) | 1983-06-29 |
| US4465622A (en) | 1984-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3223087C2 (de) | Verfahren zur Reinigung von Interferon | |
| EP1394179B1 (de) | Verfahren zur Herstellung von Erythropoietin frei von tierischen Proteinen | |
| EP0118808B1 (de) | Reinigung von Interferon | |
| DE69127384T2 (de) | Verfahren zur Reinigung von Immunserumglobulinen | |
| US4667016A (en) | Erythropoietin purification | |
| EP0447585B2 (de) | Verfahren zur Herstellung eines intravenös verträglichen Immunglobulin-G-Präparates | |
| DE60206847T2 (de) | Verfahren für die Reinigung von Interferon-Proteinen mittels Kationen-Austauschchromatographie | |
| DE3786832T2 (de) | Verfahren zur Herstellung von Immunoglobulinzubereitungen für intravenöse Injektion. | |
| DE69125035T2 (de) | Verfahren zur herstellung von interferon-alpha-2 kristallen | |
| DE3149360C2 (OSRAM) | ||
| EP0228452B1 (en) | Protein purification | |
| CH647158A5 (de) | Verfahren zur reinigung von interferon. | |
| US4541952A (en) | Purification method of human interferon | |
| JPH0586097A (ja) | 上清ｉｖ、特にｉｖ−４またはコーンフラクシヨンｖまたはそれと類似の上清または画分からヒトアルブミンを単離する方法 | |
| DE3028919C2 (OSRAM) | ||
| DE2930604C2 (de) | Verwendung von doppelstrangiger Ribonucleinsäure als Interferon-Induktor | |
| DE3319714C2 (OSRAM) | ||
| DE3434122C2 (OSRAM) | ||
| DE3515336C2 (de) | Verfahren zur Herstellung und Reinigung von â-Interferon | |
| DE117470T1 (de) | Verfahren zur herstellung von interferon (ifn-gamma) des typs 26k und 21k. | |
| DE3249215C2 (de) | Verfahren zur herstellung von humanem gamma-interferon. | |
| DE3605908C2 (OSRAM) | ||
| EP0551535A1 (en) | Process for the purification of recombinant human beta interferon, beta interferon thus purified, and pharmaceutical compositions which contain them | |
| EP0196146A2 (de) | Verfahren zur Isolierung und Reinigung von alpha-Interferonen | |
| EP0446850B1 (en) | Process for purifying recombinant human beta-interferon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| 8181 | Inventor (new situation) |
Free format text: NOBUHARA, MASAHIRO, IWATSUKI, SAITAMA, JP YAMAGUCHI, KIYOSHI, KAWAGUCHI, SAITAMA, JP MOCHIDA, EI, TOKIO/TOKYO, JP |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |